Drug Profile
Research programme: chromatin targeted therapies - Foghorn Therapeutics/ Merck & Co
Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Foghorn Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Cancer in USA
- 08 Jul 2020 Foghorn Therapeutics plans to file IND application for its first programme in 2020
- 07 Jul 2020 Foghorn Therapeutics and Merck enter licensing agreement for cancer therapeutics against transcription factor target